SCHEMBL218983

SCHEMBL218983

c1nn[nH]c2cnnc1-2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Piperazine SCHEMBL27601703 0.89
SCHEMBL949067 0.75
SCHEMBL17791784 0.74
SCHEMBL29689434 0.72
SCHEMBL23641148 0.71 MEN1 (0.36)
SCHEMBL13411815 0.69 POLB (0.33)
SCHEMBL15961413 0.67 CHRM1 (0.34)
SCHEMBL59230 0.67
SCHEMBL28785812 0.67
SCHEMBL28453473 0.66

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1765 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119661537-A Nucleoside compound, preparation method thereof, composition thereof and application of nucleoside compound in medicine 中国科学院上海药物研究所 2025-03-21 CN claimed
US-20240246959-A1 BENZIMIDAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. (CN) 2024-07-25 US claimed
CN-116998489-A Application of pyrazole triazine in preventing and controlling rice diseases 上海交通大学 2023-11-07 CN claimed
EP-4242202-A1 BENZIMIDAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF Shenzhen Salubris Pharmaceuticals Co., Ltd. (CN) 2023-09-13 EP claimed
US-20230027361-A1 METTL3 MODULATORS ACCENT THERAPEUTICS, INC. (US) 2023-01-26 US claimed
US-20220372040-A1 METTL3 MODULATORS ACCENT THERAPEUTICS, INC. (US) 2022-11-24 US claimed
CN-115298179-A METTL3 modulators 埃克森特治疗公司 2022-11-04 CN claimed
CN-115279756-A METTL3 modulators 埃克森特治疗公司 2022-11-01 CN claimed
EP-4048674-A2 METTL3 MODULATORS Accent Therapeutics, Inc. (US) 2022-08-31 EP claimed
EP-4048670-A1 METTL3 MODULATORS Accent Therapeutics, Inc. (US) 2022-08-31 EP claimed
WO-2003093290-A2 NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION GENELABS TECHNOLOGIES, INC. (US) 2003-11-13 WO claimed
US-6451825-B1 FOR THERAPY OF HYPERTENSION, A THERAPEUTIC AGENT OF ANGINA PECTORIS, A SUPPRESSIVE AGENT OF CEREBROVASCULAR CONTRACTION, ASTHMA, PERIPHERAL CIRCULATION DISORDER, AS PROPHYLACTIC AGENT OF IMMATURE BIRTH, A THERAPEUTIC AGENT OF ARTERIOSCLEROSIS MITSUBISHI PHARMA CORPORATION (JP) 2002-09-17 US claimed
EP-1195372-A1 N-heterocyclic substituted benzamide derivatives with antihypertensive activity Mitsubishi Pharma Corporation (JP) 2002-04-10 EP claimed
US-6218410-B1 ADMINISTERING A PHARMACEUTICALLY EFFECTIVE AMOUNT OF A RHO KINASE INHIBITOR COMPRISING AMIDE COMPOUND FOR INHIBITING RHO KINASE YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2001-04-17 US claimed
US-6156766-A Benzamide compounds and pharmaceutical use thereof YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2000-12-05 US claimed
EP-0269859-B2 Pyrazolotriazine compounds OTSUKA PHARMA CO LTD (JP) 1995-10-18 EP claimed
CN-1017708-B METHOD FOR PREPARATION OF PYRAZOLOTRIAZINE COMPOUNDS OTSUKA CHEMICAL CO LTD (JP) 1992-08-05 CN claimed
US-4824834-A TREATING GOUT OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) 1989-04-25 US claimed
EP-0269859-A2 Pyrazolotriazine compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1988-06-08 EP claimed
CN-87107217-A Method for preparation of pyrazolotriazine compounds 1988-05-11 CN claimed